Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Novaccess Global Inc XSNX

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is... see more

OTCQB:XSNX - Post Discussion

Novaccess Global Inc > about to take off again people!
View:
Post by keepitrealhomie on Jan 04, 2018 2:45pm

about to take off again people!

this drop was a result of Session comments. It will have zero affect on xsunx! nice and lucky consolidation. lets go!
Comment by cashmein on Jan 04, 2018 3:40pm
Very good product. California and elsewhere just starting. The growers will understand the savings made on energy, most important. Patience is the name of the game as Buffet said :)))
Comment by stealthct on Jan 04, 2018 4:09pm
what are you guys hedging a share price by March 30th?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities